Chloé Amouyal1,2, Marion Buyse3, Lea Lucas-Martini4, Déborah Hirt3,5, Laurent Genser1,6, Adriana Torcivia6, Jean-Luc Bouillot7, Jean-Michel Oppert2,4, Judith Aron-Wisnewsky8,9,10. 1. INSERM, UMRS, NutriOmicsTeam, Sorbonne Université, Paris, France. 2. Institute of Cardiometabolism and Nutrition, Institut E3M, 83 boulevard de l'Hôpital, 75013, Paris, France. 3. INSERM, Saint-Antoine Research Center, Saint-Antoine Hospital, Sorbonne Université, Paris, France. 4. Nutrition Department, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France. 5. Pharmacology Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris, Paris, France. 6. Visceral Surgery Department, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France. 7. Visceral Surgery Department, Ambroise Paré Hospital, Assistance Publique Hôpitaux de Paris, Saint Quentin Versailles University, Paris, France. 8. INSERM, UMRS, NutriOmicsTeam, Sorbonne Université, Paris, France. judith.aron-wisnewsky@aphp.fr. 9. Institute of Cardiometabolism and Nutrition, Institut E3M, 83 boulevard de l'Hôpital, 75013, Paris, France. judith.aron-wisnewsky@aphp.fr. 10. Nutrition Department, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Sorbonne Université, Paris, France. judith.aron-wisnewsky@aphp.fr.
Abstract
CONTEXT: Anti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS. OBJECTIVE: Describing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes. DESIGN, SETTING, AND PATIENTS: Prospective study of HIV patients undergoing SG in a referral academic center, with at least 6 months follow-up. MAIN OUTCOME MEASURE: Clinical and biological parameters, HIV medical history, and ART pharmacokinetics were gathered before and post-SG. RESULTS: Seventeen patients (mean BMI = 44.2 ± 5.7 kg m-2) and major obesity-related diseases (47% type-2 diabetes, 64% obstructive sleep apnea, 70% hypertension) underwent SG during a mean 2 years of follow-up. They displayed an average of 20% reduction of initial BMI and improved body composition, similarly to obese non-HIV patients. SG improved metabolic status. All patients had undetectable viral load before BS. Upon HIV follow-up, 12 patients had undetectable viral load with correct ART kinetic parameters (3 and 6 months); 4 displayed detectable viral load along with significant decrease in raltegravir and atazanavir treatment exposure, leading to ART change with subsequent undetectable viral load; and 1 had persistent detectable viral load despite ART change. CONCLUSIONS: SG seems effective and safe in obese HIV patients. However, ART treatment should be monitored post-SG to control HIV infection. We suggest that some ART should be adapted before SG conjoints with infectious disease specialists.
CONTEXT: Anti-retroviral therapy (ART) dramatically reduced AIDS development, thus enabling patients to live as long as the general population. New challenges have emerged particularly cardiometabolic diseases and weight gain, with some HIV patients seeking bariatric surgery (BS). However, BS outcomes during HIV remain poorly described, with scarce data on ART pharmacokinetic post-BS. OBJECTIVE: Describing sleeve gastrectomy (SG) results in HIV patients in terms of ART pharmacokinetic, HIV control, weight loss, and metabolic outcomes. DESIGN, SETTING, AND PATIENTS: Prospective study of HIV patients undergoing SG in a referral academic center, with at least 6 months follow-up. MAIN OUTCOME MEASURE: Clinical and biological parameters, HIV medical history, and ART pharmacokinetics were gathered before and post-SG. RESULTS: Seventeen patients (mean BMI = 44.2 ± 5.7 kg m-2) and major obesity-related diseases (47% type-2 diabetes, 64% obstructive sleep apnea, 70% hypertension) underwent SG during a mean 2 years of follow-up. They displayed an average of 20% reduction of initial BMI and improved body composition, similarly to obese non-HIVpatients. SG improved metabolic status. All patients had undetectable viral load before BS. Upon HIV follow-up, 12 patients had undetectable viral load with correct ART kinetic parameters (3 and 6 months); 4 displayed detectable viral load along with significant decrease in raltegravir and atazanavir treatment exposure, leading to ART change with subsequent undetectable viral load; and 1 had persistent detectable viral load despite ART change. CONCLUSIONS: SG seems effective and safe in obese HIVpatients. However, ART treatment should be monitored post-SG to control HIV infection. We suggest that some ART should be adapted before SG conjoints with infectious disease specialists.
Authors: Gautam Sharma; Andrew T Strong; Mena Boules; Chao Tu; Samuel Szomstein; Raul Rosenthal; John Rodriguez; Alan J Taege; Matthew Kroh Journal: Obes Surg Date: 2018-04 Impact factor: 4.129
Authors: Henry Selke; Steven Norris; Danielle Osterholzer; Kenneth H Fife; Barbara DeRose; Samir K Gupta Journal: AIDS Patient Care STDS Date: 2010-09 Impact factor: 5.078
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Marian Iwamoto; Larissa A Wenning; Goutam C Mistry; Amelia S Petry; Sarah Y Liou; Kaylan Ghosh; Sheila Breidinger; Neal Azrolan; Maria J Gutierrez; William E Bridson; Julie A Stone; Keith M Gottesdiener; John A Wagner Journal: Clin Infect Dis Date: 2008-07-01 Impact factor: 9.079
Authors: Philip Carlo Angeles; Ida Robertsen; Lars Thomas Seeberg; Veronica Krogstad; Julie Skattebu; Rune Sandbu; Anders Åsberg; Jøran Hjelmesaeth Journal: Obes Rev Date: 2019-06-24 Impact factor: 9.213